Jay Stout
Hoofd Techniek/Wetenschap/O&O bij IMMUNOVANT, INC.
Vermogen: 4 M $ op 30-04-2024
Profiel
Jay Stout is currently the Chief Technology Officer at Immunovant, Inc. He previously worked as the Chief Technical Officer at Immunomedics, Inc. and as the Senior Vice President-Technical Operations at Versartis, Inc. Stout received his undergraduate and graduate degrees from the University of Iowa and his doctorate from The University of Nebraska-Lincoln.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMMUNOVANT INC
0.10% | 24-04-2024 | 147 739 ( 0.10% ) | 4 M $ | 30-04-2024 |
Actieve functies van Jay Stout
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMUNOVANT, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2023 |
Eerdere bekende functies van Jay Stout
| Bedrijven | Functie | Einde |
|---|---|---|
| IMMUNOMEDICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Jay Stout
| The University of Nebraska-Lincoln | Doctorate Degree |
| University of Iowa | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| IMMUNOVANT, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
